A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Brentuximab Vedotin and CHP (A+CHP) versus CHOP in the Frontline Treatment of Patients with CD30- Positive Mature T-cell Lymphomas

Diseases and Conditions Researched

Non-Hodgkin's Lymphoma

What is the purpose of this trial?

This is a double-blind, randomized, multicenter, phase 3 clinical trial to compare the efficacy and safety of brentuximab vedotin in combination with CHP with the standard-of-care CHOP in patients with CD30-positive mature T-cell lymphomas.

Participation Guidelines

Age: Any

Click here for detailed participation information for this trial.

Sponsor: Seattle Genetics, Inc.
Last Updated:
Study HIC#: 1303011743